PNEUMOCOCCAL VACCINES MARKET ANALYSIS

Pneumococcal Vaccines Market, By Vaccine Type (Pneumococcal Conjugate Vaccines (PCVs) (PCV13 (Prevnar 13/Prevenar 13), PCV10 (Synflorix), PCV7 (Prevnar/Prevenar)) and Pneumococcal Polysaccharide Vaccines (PPVs) (PPSV23 (Pneumovax 23), PPSV14 (Pneumo 14)), By Target Population (Adults (≥ 65 years), Children (< 5 years), High-Risk Adults (18-64 years)), By Route of Administration (Intramuscular, Subcutaneous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Feb 2025
Code : CMI2295
Pages :150
Formats :
Excel and PDF
Industry : Biotechnology

Pneumococcal Vaccines Market Size and Trends

Global pneumococcal vaccines market is estimated to be valued at USD 9.38 billion in 2025 and is expected to reach USD 13.29 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032. Increasing awareness about prevention of pneumococcal disease can boost demand for effective vaccination. The market growth is driven by expansion of immunization programs worldwide and introduction of newer and advanced vaccines to tackle serotype replacement concerns.

Pneumococcal Vaccines Market Key Factors

To learn more about this report, Request sample copy

Market Driver - Increasing prevalence of pneumococcal diseases

Rising burden of pneumococcal diseases can drive the market growth. Streptococcus pneumoniae, also known as pneumococcus, is a major cause of morbidity and mortality worldwide. It is a leading cause of community-acquired pneumonia as well as other infections such as bacteremia, sepsis and meningitis, especially in children and the elderly population. Pneumonia is a significant cause of death among children under 5 years of age. According to the data published by WHO, pneumonia caused over 800,000 deaths in children under age of 5 years in 2019. Although vaccines are available to prevent pneumococcal diseases, it is still endemic in many developing and underdeveloped regions with inadequate access to vaccination and healthcare services. Even in developed nations, growing elderly population who are more vulnerable is becoming a key concern area. With aging population worldwide, the susceptibility to pneumococcal infections is projected to increase in the near future. This, coupled with emergence of antibiotic-resistant strains, has heightened the risks from these preventable diseases. Rising awareness about pneumococcal diseases and their prevention through vaccination programs boosts the need for effective pneumococcal vaccines across all regions. Growing threat posed by these infections warrants strengthened immunization efforts and availability of advanced generation vaccines to counter the global burden of pneumococcal diseases.